DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Omniscan (Gadodiamide) - Published Studies


Omniscan Related Published Studies

Well-designed clinical trials related to Omniscan (Gadodiamide)

Comparison of gadobenate dimeglumine and gadodiamide in the evaluation of spinal vascular anatomy with MR angiography. [2010.06]

Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: results of a phase III multicenter trial. [2010.02]

Abdominal and iliac arterial stenoses: comparative double-blinded randomized study of diagnostic accuracy of 3D MR angiography with gadodiamide or gadopentetate dimeglumine. [2006.03]

Contrast-enhanced magnetic resonance angiography of the lower extremities: standard-dose vs. high-dose gadodiamide injection. [2005.04]

Well-designed clinical trials possibly related to Omniscan (Gadodiamide)

Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging. [2011.07]

Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. [2009.06]

Intra-articular distribution pattern after ultrasound-guided injections in wrist joints of patients with rheumatoid arthritis. [2009.02]

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. [2008.10.01]

MR colonography with fecal tagging: barium vs. barium ferumoxsil. [2008.05]

Effects of ionic and non-ionic paramagnetic contrast media on brain bio-electric activity. [2005.11]

Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. [2005.08]

Intra-arterial magnetic resonance angiography of the iliac arteries: clinical experience using two different protocols. [2005.05]

Other research related to Omniscan (Gadodiamide)

Contrast-enhanced MRI of the inner ear after intratympanic injection of meglumine gadopentetate or gadodiamide hydrate. [2011.02]

Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T. [2010.12]

Evaluation of Gadodiamide Versus Gadobutrol for Contrast-Enhanced MR Imaging in a Rat Brain Glioma Model at 1.5 and 3 T. [2010.09.17]

Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. [2010.09]

The fate of Gd and chelate following intravenous injection of gadodiamide in rats. [2010.07]

Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. [2009.11]

Lack of nephrotoxicity of gadodiamide in unselected hospitalized patients. [2009.09]

MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. [2008.12]

Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. [2008.10]

MR diskography and CT diskography with gadodiamide-iodinated contrast mixture for the diagnosis of foraminal impingement. [2008.09]

Contrast-Enhanced MR Imaging of Brain Lesions: A Large-Scale Intraindividual Crossover Comparison of Gadobenate Dimeglumine versus Gadodiamide. [2008.07.03]

Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. [2008.04]

Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. [2008.03]

High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. [2008.02]

Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study. [2007.12]

Allergic reactions to gadodiamide following interventional spinal procedures: a report of 4 cases. [2007.11]

Case-control study of gadodiamide-related nephrogenic systemic fibrosis. [2007.11]

Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. [2007.10.01]

Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): A phase II study. [2007.04.03]

Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). [2007.02]

MR imaging of the lymphatic system: distribution and contrast enhancement of gadodiamide after intradermal injection. [2006.12]

Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. [2006.09]

Dialyzability of gadodiamide in hemodialysis patients. [2006.07]

Safety of gadodiamide mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography. [2006.05]

Gadodiamide-based coronary angiography in a patient with severe renal insufficiency. [2005.10]

Other possibly related research studies

Diskography: infectious complications from a series of 12,634 cases. [2006.10]

Fast magnetization-driven preparation for imaging of contrast-enhanced coronary arteries during intra-arterial injection of contrast agent. [2006.11]

Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. [2006.11]

Pulmonary circulation: contrast-enhanced 3.0-T MR angiography--initial results. [2006.09]

High-resolution imaging of the intracranial arterial and venous systems following a single contrast injection. [2006.08]

Dynamic pulmonary perfusion and flow quantification with MR imaging, 3.0T vs. 1.5T: initial results. [2006.08]

Quantitative diffusion imaging in breast cancer: a clinical prospective study. [2006.08]

Intravenous contrast-enhanced dynamic MR urography: diagnosis of vesicoureteral reflux during bladder filling with time-signal intensity curves. [2006.08]

Gadolinium use in spine procedures for patients with allergy to iodinated contrast--experience of 127 procedures. [2006.06]

Contrast-enhanced 3D MRI of lung perfusion in children with cystic fibrosis--initial results. [2006.10]

Enhancement effects of test injection with a small amount of MR contrast medium in the oral and maxillofacial region. [2006.09]

Indirect magnetic resonance lymphangiography in patients with lymphedema preliminary results in humans. [2006.09]

Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. [2006.03]

Longitudinal mapping of mouse cerebral blood volume with MRI. [2006.08]

Diagnosis of perfusion abnormality of the pulmonary artery in Takayasu's arteritis using contrast-enhanced MR perfusion imaging. [2006.07]

Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. [2006.02]

Efficacy of spectral presaturation of inversion recovery in evaluating delayed myocardial enhancement. [2005.10]

Demonstration of cardiac involvement of sarcoidosis by contrast-enhanced multislice computed tomography and delayed-enhanced magnetic resonance imaging. [2005.11]

Contrast-enhanced high-resolution magnetic resonance imaging of autologous cartilage implants of the knee joint. [2005.07]

Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. [2005.11]

Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. [2005.08]

Prevalence study of proximal vertebral artery stenosis using high-resolution contrast-enhanced magnetic resonance angiography. [2005.05]

Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound. [2006.01]

"Black" contrast effect during magnetic resonance arthrography attributable to inadvertent administration of excessive gadolinium chelates. [2005.05]

MR-guided percutaneous intramyocardial injection with an MR-compatible catheter: feasibility and changes in T1 values after injection of extracellular contrast medium in pigs. [2005.05]

'Gadolinium' as an alternative to iodinated contrast media for X-ray angiography in patients with severe allergy. [2005.04]

Balloon sizing and transcatheter closure of acute atrial septal defects guided by magnetic resonance fluoroscopy: assessment and validation in a large animal model. [2005.03]

The effect of intravenous gadolinium-DTPA on diffusion-weighted imaging. [2006.07]

Comparison of ultrasmall superparamagnetic iron oxide particles and low molecular weight contrast agents to detect rejecting transplanted hearts with magnetic resonance imaging. [2005.10]

Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. [2005.03]

The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. [2007.04]

Contrast-enhanced FLAIR imaging in combination with pre- and postcontrast magnetization transfer T1-weighted imaging: usefulness in the evaluation of brain metastases. [2007.03]

Visualization of endolymphatic hydrops in patients with Meniere's disease. [2007.03]

Comparison of delayed myocardial enhancement in the early and late phase after contrast injection: is it possible to reduce the examination time for myocardial viability study? [2007.02]

Nephrogenic systemic fibrosis: risk factors and incidence estimation. [2007.04]

Evaluation of vascular complications of pancreas transplantation with high-spatial-resolution contrast-enhanced MR angiography. [2007.02]

High-resolution vascular imaging of the rat spine using liposomal blood pool MR agent. [2007.01]

Irreversible myocardial injury: assessment with cardiovascular delayed-enhancement MR imaging and comparison of 1.5 and 3.0 T--initial experience. [2007.03]

Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. [2007.02]

Shoulder MR arthrography: in vitro determination of optimal gadolinium dilution as a function of field strength. [2007.01]

Dynamic imaging of contrast-enhanced coronary vessels with a magnetization prepared rotated stripe keyhole acquisition. [2007.01]

Dual-bolus approach to quantitative measurement of pulmonary perfusion by contrast-enhanced MRI. [2006.12]

Contrast-enhanced adenosine-stress magnetic resonance imaging--feasibility and practicability of a protocol for detection or exclusion of ischemic heart disease in an outpatient setting. [2006.09]

Magnetic resonance imaging findings in patients with medial epicondylitis. [2005.04]

Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. [2007.05.08]

Magnetic resonance imaging of lymphatic vessels without image subtraction: a practicable imaging method for routine clinical practice? [2007.03]

Intra-articular distribution pattern after ultrasound-guided injections in wrist joints of patients with rheumatoid arthritis. [2007.10.10]

Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. [2007.08]

Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. [2007.03]

Good MRI images: to Gad or not to Gad? [2007.09]

Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model. [2007.07]

MR shoulder arthrography in patients younger than 40 years of age: frequency of rotator cuff tear versus labroligamentous pathology. [2007.06]

[Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper] [2007.06]

Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. [2007.10]

Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. [2007.09]

[Nephrogenic systemic fibrosis and gadolinium-based contrast media] [2007.03]

The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis. [2007.12.12]

[Nephrogenic systemic fibrosis--a new interdisciplinary challenge] [2007.12]

Histomorphological Changes after Renal X-Ray Arteriography Using Iodine and Gadolinium Contrast Media in an Ischemic Porcine Model. [2007.10.23]

Signal intensity of normal breast tissue at MR mammography on midfield: Applying a random coefficient model evaluating the effect of doubling the contrast dose. [2007.10.23]

Assessment of vasculature of meningiomas and the effects of embolization with intra-arterial MR perfusion imaging: a feasibility study. [2007.10]

Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. [2007.09]

Spatio-temporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound. [2007.09.21]

Anaphylaxis to gadobenate dimeglumine (Multihance): a case report. [2007]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017